Silent thyroiditis pathophysiology

Jump to navigation Jump to search

Xyz Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Xyz from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Silent thyroiditis pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Silent thyroiditis pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Silent thyroiditis pathophysiology

CDC on Silent thyroiditis pathophysiology

Silent thyroiditis pathophysiology in the news

Blogs on Silent thyroiditis pathophysiology

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Silent thyroiditis pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Furqan M M. M.B.B.S[2]

Overview

The exact pathogenesis of [disease name] is not fully understood.

OR

It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].

OR

[Pathogen name] is usually transmitted via the [transmission route] route to the human host.

OR

Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.

OR


[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].

OR

The progression to [disease name] usually involves the [molecular pathway].

OR

The pathophysiology of [disease/malignancy] depends on the histological subtype.

Pathophysiology

The control, synthesis, and release of the thyroid hormone is usually controlled by hypothalamus and pituitary gland.[1][2]

Pathogenesis

  • The exact pathogenesis of silent thyroiditis is not fully understood. It is thought that silent thyroiditis is the result of an autoimmune phenomenon. The following evidences are suggestive of an autoimmune pathogenesis of silent thyroiditis.[3][4][5][6]
    • Lymphocytic infiltration of the thyroid gland
    • Presence of antithyroid antibodies
    • Association with HLA-DR3 and DR5
    • Presence of anti-DNA antibodies
  • Activated matured T (HLA-DR+CD3+), activated helper/inducer T (HLA-DR+CD4+) and activated suppressor/cytotoxic T (HLA-DR+CD8+) cells were higher in patients with silent thyroiditis as compared to the healthy controls. It indicates that the activation of T cells, especially of helper/inducer T cells, might have an important role in the pathogenesis of silent thyroiditis.[7]

Genetics

Silent thyroiditis is associated with the following HLA genes.[5]

  • HLA-DR3
  • HLA-DR5

Associated Conditions

Gross Pathology

  • On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

Microscopic Pathology

  • Microscopic histopathological findings in silent thyroiditis include:[3][8]
  • Diffuse lymphocytic infiltrate
  • Lack of Hurthle cells (Askanazy cells) and germinal centers
  • Lack of fibrosis

References

  1. De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, Rousset B, Dupuy C, Miot F, Dumont J. "Thyroid Hormone Synthesis And Secretion". PMID 25905405.
  2. Kirsten D (2000). "The thyroid gland: physiology and pathophysiology". Neonatal Netw. 19 (8): 11–26. doi:10.1891/0730-0832.19.8.11. PMID 11949270.
  3. 3.0 3.1 Volpé R (1988). "Is silent thyroiditis an autoimmune disease?". Arch. Intern. Med. 148 (9): 1907–8. PMID 3415401.
  4. Samuels MH (2012). "Subacute, silent, and postpartum thyroiditis". Med. Clin. North Am. 96 (2): 223–33. doi:10.1016/j.mcna.2012.01.003. PMID 22443972.
  5. 5.0 5.1 Farid NR, Hawe BS, Walfish PG (1983). "Increased frequency of HLA-DR3 and 5 in the syndromes of painless thyroiditis with transient thyrotoxicosis: evidence for an autoimmune aetiology". Clin. Endocrinol. (Oxf). 19 (6): 699–704. PMID 6606505.
  6. Tajiri J, Higashi K, Morita M, Ohishi S, Umeda T, Sato T (1986). "Elevation of anti-DNA antibody titer during thyrotoxic phase of silent thyroiditis". Arch. Intern. Med. 146 (8): 1623–4. PMID 3488044.
  7. Kushima K, Ban Y, Taniyama M, Itoh K (1994). "Circulating activated T lymphocyte subsets in patients with silent thyroiditis". Endocr. J. 41 (6): 663–9. PMID 7704090.
  8. Mittra ES, McDougall IR (2007). "Recurrent silent thyroiditis: a report of four patients and review of the literature". Thyroid. 17 (7): 671–5. doi:10.1089/thy.2006.0335. PMID 17696838.

Template:WH Template:WS